Bril F, et al. - In the study, individuals with non-alcoholic steatohepatitis (NASH, n = 121) who took part in our former randomized controlled trials of pioglitazone with complete paired data for intrahepatic triglyceride (IHTG) content by MR spectroscopy and liver histology were involved in order to build how reliable this approach was to prognosticate advances in liver histology in persons with NASH. Variations in IHTG associated with steatosis on histology. Nonetheless, neither in individuals receiving pioglitazone nor placebo, the magnitude of IHTG decrease was not related to the rate of response of the primary histological outcome or the resolution of NASH without worsening of fibrosis. Despite the treatment arm, variations in lobular inflammation, hepatocyte ballooning, or liver fibrosis were also independent of variations in IHTG. Steatosis resolution was not correlated with superior histological outcomes either. In conclusion, alterations in IHTG prognosticate changes in steatosis however, not of other liver histological parameters. This designates that in individuals with NASH, the IHTG response to treatment should be deciphered with care, as it could not be as secure as formerly considered in order to prognosticate a treatment’s overall clinical efficiency.